Pulmonary hypertension (PH) is a rare and fatal cardiopulmonary disease that disproportionately impacts women. Despite the progress in the diagnosis, clinical care, and treatment of PH, unique etiological factors are still being discovered. Iatrogenic forms of PH are one of the leading but under-appreciated causes of the disease in the modern era. This symposium will provide expertise from the following: Stanford University, international academic centers as well as the broader academic communities, including global organizations (World Health Organization, United States Food and Drug Administration, European Medicines Agency), and stakeholders (patients, industry partners, etc.) to develop a deeper understanding of “drug-induced pulmonary hypertension” and establish pharmacovigilance protocols for monitoring drug safety and rapid identification of PH in at-risk populations.

Registration

There are two ways to attend this hybrid activity: in-person or virtually.

1. In-Person
Registration Fees (Includes course materials, breakfast and lunch, and a certificate of participation).

• Physician/AHP/RN - $399
• Student - $199
• Industry (non-sponsor) - $1,500

2. Virtually
Registration Fees (Join virtually, via Zoom. Fees include course material and a certificate of participation. You will receive your Zoom link the week of the symposium).

• Physician/AHP/RN - $399
• Student - $199
• Industry (non-sponsor) - $1,500

Tuition may be paid by Visa or MasterCard. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. Be sure to include an email address that you check frequently.

STAP-eligible employees can use STAP funds towards the registration fees for this activity.  Complete the STAP Reimbursement Request Form and submit to your department administrator. 

Credits

AMA PRA Category 1 Credits™ (12.25 hours), Non-Physician Participation Credit (12.25 hours)

Target Audience

• Specialties - Critical Care & Pulmonology
• Professions - Fellow/Resident, Medical Student, Non-Physician, Physician

Objectives

At the conclusion of this activity, learners should be able to:

• Consider the various forms of pulmonary hypertension, based on the classifications of the World Health Organization.
• Develop skills/strategies to identify at risk patients for pulmonary hypertension.
• Identify drug classes and types linked to pulmonary arterial hypertension.
• Understand drug-associated mechanisms of toxicity linked to the development of pulmonary arterial hypertension.
• Learn pharmacovigilance methods and strategies that can help uncover existing and future pulmonary vascular related drug toxicity.

Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Live Activity for a maximum of 12.25 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.